Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Kiniksa Pharmaceuticals International, plc (KNSA) points to a 29.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Kiniksa Pharmaceuticals International, Plc (KNSA) Presents At Citi's Biopharma Back To School Conference Transcript
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Citi's Biopharma Back to School Conference September 3, 2025 9:00 AM EDT Company Participants Sanj Patel - CEO & Chairman of the Board Ross Moat - Executive VP & Chief Commercial Officer John Paolini - Executive VP & Chief Medical Officer Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director Welcome to the second day of the Citi Biopharma and Back-to-school Conference. This is our 20th annual.
Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade
The consensus price target hints at a 26.7% upside potential for Kiniksa Pharmaceuticals International, plc (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know
Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Just The Tonic: This Medical Stock, A Mutual Fund Darling, Tests Entry Amid 58% Run
A good medical stock can help diversify a portfolio. This particular name is testing a fresh entry as funds pile in.
Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect?
The mean of analysts' price targets for Kiniksa Pharmaceuticals International, plc (KNSA) points to a 36% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
Kiniksa Pharmaceuticals International, plc (KNSA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q2 2025 Earnings Call July 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Officer Mark A. Ragosa - Senior VP & CFO Ross Michael Moat - Executive VP & Chief Commercial Officer Sanj K.
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to a loss of $0.06 per share a year ago.
Kiniksa Pharmaceuticals: Making Steady Progress
Kiniksa Pharmaceuticals posted strong Q1 results last week, beating expectations and raising 2025 ARCALYST net sales guidance to $590-$605 million, up from $560-$580 million. Analyst firms are optimistic, with firms like Goldman Sachs, Wedbush, and Jefferies assigning Buy ratings and price targets ranging from $32 to $45 on the shares. Kiniksa also has a solid balance sheet with nearly $270 million in cash and no long-term debt.
